Can Antitrust Laws Prevent Abuse Of FDA REMS Programs?

A New Jersey federal court will be deciding whether a brand-name firm violates antitrust laws when it delays generic brand entry by not distributing samples of its patented drug to competitors who need the samples to receive U.S. Food and Drug Administration more

  • Tags: